Published

Impact of Psilocybin on Peripheral Cytokine Production.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychedelic medicine (New Rochelle, N.Y.)
Date: 2024-06-01
Source: PubMed
DOI: 10.1089/psymed.2023.0039
PubMed: 40051582

Authors

DiRenzo D Barrett FS Perin J Darrah E Christopher-Stine L Griffiths RR

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction Clinical Trial Randomized Controlled Trial Inflammation Immune Function Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine2026-05-01 Impact of Psilocybin on Peripheral Cytokine Production.2024-06-01

Related papers

Alternative therapy for neurological and psychiatric disorders using psilocybinSão Paulo Medical Journal · 2025-01-01 Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent EvidenceCurrent Psychopharmacologye · 2024-07-04 Psychedelics: The New Kid on the BlockAnnals of Indian Psychiatry · 2024-01-01 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05 Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive MechanismsClinicalTrials.gov · 2024-08-07 Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive DisorderInternational Journal of Mental Health and Addiction · 2024-03-07 Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority TrialResearch Square · 2024-01-04